The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For ...

An aged helicopter fleet and inexperienced pilots from nearby Fort Belvoir had raised “widespread concern” among local pilots ...

Ross Chastain detailed NASCAR’s racing costs and how he and his father managed the climb from Late Models to Trucks, Xfinity, ...

Stretched fuselage, tight tail-strike margins, and high wing loading force the aircraft to spend more time getting up to ...

Fundamentally, Lucid continues to face production limits that cap near-term upside despite improving deliveries. The company ...

Bold corporate announcements often precede real capability, leaving leaders to navigate the space between ambition and ...

Plug Power is cutting cash burn and improving margins, yet still faces profitability challenges. Click here to read my most ...

Cake Equity reports that to successfully fundraise in 2026, startups need clear documentation, organized records, and strong ...

If you are wondering whether Zevra Therapeutics is a comeback story in the making or a value trap in disguise, you are in the right place to dig into what the market is really pricing in. The stock ...

Davis revealed in a 2024 Instagram post that he was “given a second chance at life” after surviving a shooting on August 19, ...

Discover Rigetti’s quantum computing growth prospects, revenue updates, and funding outlook. Learn if now is the right time ...

Here, as selected by the Wallpaper* style team, are the 25 fashion moments that defined the zeitgeist in 2025 – from a viral ...